Chromium picolinate is an orally administered trivalent chromium complex used as a source of chromium and studied mainly in human research on Diabetes and Glycemic Control, with secondary evidence in Obesity and Weight Regulation, Women’s Health in PCOS, and a smaller amount of Liver Health research. (Research) (Review)
Chromium picolinate is best characterized in human research as a direct-use compound rather than an endogenous biomarker. Human evidence is strongest in type 2 diabetes and related insulin-resistance settings, where randomized trials and meta-analyses report recurring but mixed signals. Evidence for weight-related outcomes is smaller and less consistent, PCOS has a narrower but supportive trial base, and liver-metabolic research remains limited to a small pilot study in a MASLD context. Overall, the cited literature is usable but not fully mature because results vary across populations, doses, and outcomes, and long-term safety characterization remains incomplete. (Review) (Review) (Research)
Ingredient Snapshot
- Entity: Chromium Picolinate
- Chemical or biological class: Trivalent chromium coordination complex with picolinic acid ligand (Review)
- Endogenous vs exogenous: Exogenous administered chromium source; chromium is a trace mineral, while chromium picolinate is a manufactured delivery form (NIH ODS)
- Primary human research domains: Diabetes and Glycemic Control; Obesity and Weight Regulation; Women’s Health (PCOS) (Research) (Review) (Review)
- Common study formats: Randomized placebo-controlled trials, meta-analyses, and smaller pilot studies (Review) (Review)
- Pharmacokinetic characterization status: Limited; human exposure data exist, but full pharmacokinetic characterization is modest (Research) (Review)
- Regulatory context (U.S./EU): In the U.S., the cited FDA source provides food-use GRAS context and does not constitute drug approval or efficacy evaluation. In the EU, the cited EFSA source provides food-use safety and bioavailability context rather than medicinal approval. (FDA) (EFSA)
Research Snapshot
Chromium picolinate is a chromium delivery form studied primarily for glycemic and insulin-resistance-related outcomes in humans. The strongest human literature is in Diabetes and Glycemic Control, especially type 2 diabetes, where randomized trials and meta-analyses show recurring but not uniformly consistent improvements in glucose-related markers in some populations. Secondary human evidence exists in Women’s Health for PCOS and in Obesity and Weight Regulation, but these areas are narrower and generally less robust than the diabetes literature. (Review) (Review) (Review)
Typical studied human exposures in the cited trials range from 200 mcg/day to 1,000 mcg/day, with most intervention studies using oral chromium picolinate for weeks to months rather than acute dosing. A main limitation is that the evidence base is heterogeneous: positive signals are more common in selected insulin-resistant or type 2 diabetes populations, while trials in normoglycemic adults, metabolic syndrome, and some weight-loss settings have reported neutral findings. Pharmacokinetic coverage is also modest, so interpretation relies more on clinical trial outcomes than on a well-defined human PK profile. (Research) (Research) (Research) (Research)
Overall, the cited human evidence is best described as limited to moderate and mixed by population, with the clearest recurring signals in glycemic-control research rather than across all metabolic uses. (Review) (Review)
Introduction
Chromium picolinate is a synthetic complex made by binding trivalent chromium to picolinic acid, and it is used in research and commercial products as a source of chromium rather than as a naturally occurring food compound in that exact form. Chromium itself is a trace mineral present in foods, but the picolinate form is a manufactured delivery format intended to improve chromium provision. (NIH ODS) (Review)
People usually look up chromium picolinate because it has been studied for glucose metabolism, insulin sensitivity, body-weight-related outcomes, and PCOS-related metabolic measures. Human interest in the ingredient comes mainly from trials in type 2 diabetes and related insulin-resistance settings, but the cited evidence also shows important inconsistency across populations and outcomes. (Review) (Review) (Review)
This article is informational only, describes the ingredient as a biochemical substance studied in human research, and does not provide medical or dosing advice. (NIH ODS)
Quick Summary
- Chromium picolinate is a manufactured oral form of trivalent chromium used as a chromium source in human research and commercial products. (NIH ODS) (Review)
- The strongest human research area is Diabetes and Glycemic Control, where some randomized trials and meta-analyses report improvement in glycemic markers, but results are not uniform across all studies or populations. (Review) (Review)
- Evidence for Obesity and Weight Regulation is mixed and generally shows small or clinically uncertain effects on body weight. (Review) (Review)
- In women with PCOS, human trials suggest possible improvement in some insulin-related and hormonal measures, but the evidence base is still limited. (Research) (Review)
- Liver-metabolic research exists, but current cited evidence in MASLD is limited to a small pilot trial with mixed findings across biomarkers and imaging-related outcomes. (Research)
- Human studies have used oral doses from 200 mcg/day to 1,000 mcg/day, with limited pharmacokinetic characterization compared with the size of the efficacy literature. (Research) (Research)
- U.S. and EU regulatory context in the cited sources is food-use and safety-framework oriented, not drug-approval oriented. (FDA) (EFSA)
Human Research Findings by Condition
Diabetes and Glycemic Control
Human evidence for chromium picolinate is strongest in Diabetes and Glycemic Control, but the findings are mixed across populations and study designs. Positive results are more often reported in type 2 diabetes or insulin-resistant populations, whereas trials in normoglycemic adults and some at-risk groups have been neutral. (Review) (Review)
Dose studied: 1,000 mcg/day
Population: 180 adults with type 2 diabetes
Duration: 4 months
Study summary:
Researchers compared placebo, 200 mcg/day, and 1,000 mcg/day chromium picolinate in adults with type 2 diabetes. The higher-dose group showed larger improvements in HbA1c, fasting glucose, 2-hour glucose, and some insulin-related measures over the study period. This finding is limited to the study population and duration.
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: (Research)
Optional supporting context citation: (Review)
- —
Dose studied: 600 mcg/day
Population: 71 adults with poorly controlled type 2 diabetes
Duration: 4 months
Study summary:
In this placebo-controlled trial, chromium picolinate was studied in adults whose diabetes control was suboptimal at baseline. The treated group had lower fasting glucose, postprandial glucose, and lower post-treatment HbA1c than the placebo group. This result applies only within the conditions of the cited study.
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: (Research)
Endocrine Health
Human studies in insulin-resistant endocrine conditions have focused mainly on metabolic syndrome and related dysglycemia-risk states. The overall signal is mixed, with neutral findings in some metabolic syndrome trials and mixed results in prevention-risk populations. (Research) (Research)
Dose studied: 1,000 mcg/day
Population: Obese nondiabetic adults with metabolic syndrome
Duration: 16 weeks
Study summary:
This randomized trial evaluated chromium picolinate in adults with metabolic syndrome and used insulin sensitivity as the primary endpoint. The intervention did not improve the main insulin sensitivity measure or most metabolic syndrome features compared with placebo. This evidence does not establish long-term or general-population effects.
Result: Human clinical study reported no clear effect
Evidence strength: Moderate
Study source: (Research)
- —
Dose studied: 500 or 1,000 mcg/day
Population: Adults with impaired fasting glucose, impaired glucose tolerance, or metabolic syndrome
Duration: Modified cross-over trial
Study summary:
Researchers studied chromium picolinate in adults at elevated diabetes risk rather than established diabetes. The trial contributes to the mixed evidence base because it did not provide a clearly consistent prevention-oriented signal across outcomes. The findings are specific to the study design and may not generalize beyond it.
Result: Human clinical studies reported mixed findings
Evidence strength: Mixed
Study source: (Research)
Obesity and Weight Regulation
Human research on chromium picolinate for Obesity and Weight Regulation has generally reported small, inconsistent, or neutral effects. Meta-analyses describe at most a modest body-weight signal, and several individual trials did not find meaningful body-composition improvement. (Review) (Review)
Dose studied: 400 mcg/day
Population: Overfat active-duty Navy personnel
Duration: 16 weeks
Study summary:
This randomized trial tested oral chromium picolinate in active-duty personnel with excess body fat. The study did not find greater reductions in body weight or body fat versus placebo over 16 weeks. This result applies only within the conditions of the cited study.
Result: Human clinical study reported no clear effect
Evidence strength: Moderate
Study source: (Research)
- —
Dose studied: 200 mcg/day
Population: Women consuming nutritionally balanced diets
Duration: 12 weeks
Study summary:
In this controlled feeding study, chromium picolinate was examined in women under a structured diet setting. The trial did not support claims that the ingredient meaningfully changed body weight or body composition in this context. This evidence does not establish long-term or general-population effects.
Result: Human clinical study reported no clear effect
Evidence strength: Moderate
Study source: (Research)
Women’s Health
Human evidence in Women’s Health is centered on polycystic ovary syndrome, where chromium picolinate has been studied for insulin-related and reproductive measures. The available trial and meta-analytic evidence is more supportive than the weight-loss literature, but it is still limited by the size and breadth of the trial base. (Research) (Review)
Dose studied: 1,000 mcg/day
Population: Women with polycystic ovary syndrome
Duration: 6 months
Study summary:
This randomized study evaluated chromium picolinate in women with PCOS and tracked metabolic as well as ovulatory outcomes. The intervention was associated with lower fasting insulin, an improved fasting glucose-insulin ratio, lower BMI, and higher ovulation and menstrual regularity during the study. This finding is limited to the study population and duration.
Result: Human clinical study reported a modest improvement
Evidence strength: Moderate
Study source: (Research)
Optional supporting context citation: (Review)
Liver Health
Human research in Liver Health is limited and currently anchored by a small pilot trial in MASLD, formerly NAFLD/NASH terminology in older literature. The cited study reported improvement in some insulin-resistance, triglyceride, and inflammatory markers, but not in fasting glucose, HbA1c, or steatosis intensity. (Research)
Dose studied: 400 mcg/day
Population: 46 adults with fatty liver disease
Duration: 3 months
Study summary:
Researchers studied chromium picolinate in adults with fatty liver disease in a pilot randomized design. Some metabolic and inflammatory markers improved, but imaging-related steatosis intensity and several glycemic endpoints did not clearly improve. This evidence does not establish long-term or general-population effects.
Result: Human clinical studies reported mixed findings
Evidence strength: Limited
Study source: (Research)
Dosage & Study Snapshot (Research Context)
Human exposure research on chromium picolinate is based mainly on oral intervention trials rather than dietary intake studies of chromium picolinate itself, because this specific form is manufactured rather than naturally consumed as such. The cited human literature spans 200 mcg/day to 1,000 mcg/day, with lower exposures appearing in biomonitoring and some clinical trials, and higher exposures used mainly in diabetes, metabolic syndrome, and PCOS trials. The overall exposure pattern is therefore a direct-use oral trial literature, not a food-intake literature, and the lowest documented exposure is useful for context but is not the main anchor of the broader efficacy data. (Research) (Research) (Research)
At the low end of the cited human exposure range, 200 mcg/day has been documented both in a small biomonitoring study and in clinical trials. In 6 volunteers, this intake increased urinary chromium above background, showing measurable systemic exposure at a low oral dose. In adults with type 2 diabetes, a 200 mcg/day trial arm also showed some glucose and insulin improvements over 4 months, although larger effects were reported at 1,000 mcg/day. A controlled feeding trial in women also used 200 mcg/day for 12 weeks and did not support weight-loss or body-composition claims. This band therefore provides lower-range exposure context, but it is not the main anchor of the broader intervention literature. (Research) (Research)
Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: Evidence at this range combines very small exposure studies with mixed clinical findings from different populations.
A 400 mcg/day dose has been studied in both weight-related and liver-metabolic settings. In overfat Navy personnel, 16 weeks at this dose did not improve body weight or body fat versus placebo. In a small 3-month MASLD pilot trial, the same daily dose improved some insulin-resistance, triglyceride, and inflammatory markers but did not improve steatosis intensity, fasting glucose, or HbA1c. This dose band shows that the same nominal regimen can produce different findings depending on the population and outcome being measured. (Research) (Research)
Result: Mixed findings
Evidence strength: Limited
Notes / limitations: The liver-metabolic signal comes from a small pilot study, while the weight-focused trial was neutral.
A 500 mcg/day exposure appears in adults at elevated risk for diabetes in a modified cross-over trial. In that setting, chromium picolinate contributed to a mixed evidence pattern rather than a clearly positive prevention signal. A related placebo-controlled trial in normoglycemic non-obese adults used 500 mcg twice daily for 16 weeks and did not improve insulin sensitivity overall, showing that higher exposure did not necessarily translate into benefit outside insulin-resistant populations. (Research) (Research)
Result: Neutral overall findings
Evidence strength: Moderate
Notes / limitations: Findings in this range are population-dependent and are not consistently favorable.
At 600 mcg/day, the human evidence includes both a diabetes trial and a narrower pilot study in overweight adults with binge-eating disorder. In poorly controlled type 2 diabetes, 4 months of this dose was associated with lower fasting glucose, postprandial glucose, and HbA1c versus placebo. In the smaller pilot setting outside the core diabetes literature, the same dose was associated with improved glucose AUC, but that evidence is contextual and not sufficient to define the ingredient’s main research identity. (Research) (Research)
Result: Modest improvement
Evidence strength: Moderate
Notes / limitations: The stronger support at this dose comes from the type 2 diabetes population rather than from broader metabolic use.
The highest repeated dose in the cited library is 1,000 mcg/day, and this is the most common upper-range regimen in the intervention literature. In type 2 diabetes, this dose was associated with stronger improvements in HbA1c, fasting glucose, 2-hour glucose, and insulin-related measures in one 4-month trial, and it also improved insulin sensitivity and attenuated weight gain when added to sulfonylurea therapy over 6 months. However, 1,000 mcg/day did not improve the primary insulin sensitivity endpoint in obese nondiabetic adults with metabolic syndrome, while a PCOS trial reported improvement in insulin-related and ovulatory outcomes. (Research) (Research)
Result: Mixed findings
Evidence strength: Moderate
Notes / limitations: This upper range has the richest evidence base, but results still differ by population and endpoint.
Key Takeaways from Human Research
- Human evidence is strongest for Diabetes and Glycemic Control, especially in type 2 diabetes, but even there the results are not uniformly positive across all trials and reviews. (Research) (Review)
- Trials in normoglycemic adults and metabolic syndrome have reported neutral findings, which limits broad generalization across all metabolic populations. (Research) (Research)
- Evidence in PCOS is narrower but more supportive than the weight-loss literature, with reported improvements in some insulin-related and reproductive measures. (Research) (Review)
- Weight-related outcomes show at most small or inconsistent effects, and several controlled trials were neutral. (Research) (Review)
- MASLD evidence remains preliminary because the cited liver-metabolic literature is limited to a small pilot study with mixed outcome findings. (Research)
- Human trial doses commonly range from 200 mcg/day to 1,000 mcg/day, but pharmacokinetic and long-term safety characterization are less developed than the efficacy literature. (Research) (NIH ODS)
Ingredient Identity
- Official name(s): Chromium picolinate
- Synonyms: Chromium(III) picolinate; trivalent chromium picolinate (Review)
- Classification: Chromium coordination complex used as a source of chromium (NIH ODS)
- CAS number (if available): Not clearly established in the cited sources
- Endogenous vs exogenous (if applicable): Exogenous delivery form of chromium; not an endogenous molecular form (NIH ODS)
Origin & Natural Occurrence
Chromium picolinate is not the naturally occurring food form of chromium. It is a manufactured complex in which trivalent chromium is combined with picolinic acid to create a specific oral delivery format used in research and commercial products. (Review)
Chromium itself is present in foods as a trace mineral, and U.S. dietary reference discussions concern chromium intake more broadly rather than chromium picolinate specifically. The cited NIH ODS source summarizes food sources and intake context for chromium, while the picolinate form is a formulated ingredient rather than a native dietary compound. (NIH ODS)
Manufacturing origin matters because many human trials in this article evaluated oral chromium picolinate rather than dietary chromium from foods. That distinction is important when interpreting the literature, since trial results on chromium picolinate should not automatically be read as findings about ordinary food chromium intake. (Review)
How It Behaves in the Body
Chromium picolinate is studied as a way to deliver chromium into the body, with most interest centered on glucose handling and insulin-related biology. In plain language, the research question is whether this chromium complex can influence how the body responds to insulin and processes glucose, especially in people with insulin resistance or type 2 diabetes. (Review) (Review)
Mechanistically, chromium has been discussed in relation to insulin signaling, meaning the chain of events by which insulin helps cells take up and use glucose. The cited reviews describe this mechanistic rationale as broader than the clinical-trial evidence, which is one reason the human literature remains mixed despite longstanding biological interest. (Review) (Review)
Human findings also suggest that biological response may depend on baseline metabolic state. Trials in type 2 diabetes have reported improvements in glycemic markers more often than trials in normoglycemic adults, implying that any measurable physiological effect may be more apparent in insulin-resistant settings than in metabolically healthy populations. (Research) (Research)
What is well established from the cited sources is that chromium picolinate can provide measurable chromium exposure and has been repeatedly studied in oral trials. What remains less established is a consistent mechanism-to-outcome pathway that predicts who will respond, at what dose, and with what long-term clinical significance. (Research) (Review)
Absorption & Delivery Formats
Oral immediate-release
The cited human literature is dominated by oral chromium picolinate capsules or tablets used in standard intervention trials. This is the main delivery format across diabetes, metabolic syndrome, PCOS, weight, and pilot liver-metabolic studies. (Research) (Research)
Oral extended-release
The cited sources do not clearly establish a distinct extended-release clinical literature for chromium picolinate. Available human evidence is therefore best interpreted as standard oral dosing rather than release-technology-specific research. (Review)
Sublingual
The cited library does not provide meaningful human sublingual research for chromium picolinate. Evidence is limited to oral administration contexts. (Review)
Transdermal
The cited library does not provide human transdermal delivery research for chromium picolinate. Current discussion is therefore limited to oral exposure formats. (Review)
Injectable / IV (research or clinical only)
The cited library does not provide injectable or intravenous human clinical-use evidence for chromium picolinate. The article’s evidence base is therefore not an injectable pharmacology literature. (Review)
Quick Facts at a Glance
Onset (reported)
The cited literature does not define a precise acute onset window for chromium picolinate in the way that drug PK studies often do. Most human trials assessed changes over weeks to months, so reported effects are better understood as medium-term trial outcomes rather than rapid symptomatic onset. (Research) (Research)
Time to peak (Tmax)
A clear human Tmax for chromium picolinate is not well characterized in the cited library. The available low-dose exposure study supports measurable absorption through increased urinary chromium, but it does not provide a fully developed clinical Tmax profile. (Research)
Half-life (t½)
The cited sources do not provide a well-established human half-life for chromium picolinate suitable for routine clinical reference. This is one reason its PK characterization remains modest compared with the intervention literature. (Research) (Review)
Typical duration
Most cited intervention studies lasted from 8 weeks to 6 months, with common durations around 3 to 4 months. This means the human literature is oriented toward short- to medium-term metabolic outcomes rather than long-term maintenance data. (Research) (Research)
Absorption routes studied
Human research in the cited library reflects oral administration only. The low-dose urinary chromium study supports that oral ingestion produces measurable exposure, but broader comparative absorption-route data are not available in the cited sources. (Research)
Formulation differences
The article’s core evidence is formulation-specific because most cited human trials used chromium picolinate rather than other chromium salts or food chromium exposure. That improves internal consistency for this article, but it also means the findings should not automatically be generalized to every chromium formulation. (Review) (NIH ODS)
Variability drivers
Population differences appear to be a major driver of variability. Positive findings are more common in people with type 2 diabetes or insulin resistance, while normoglycemic adults, some metabolic syndrome cohorts, and some weight-focused trials have shown neutral results. (Research) (Research) (Research)
Tolerance / adaptation
The cited library does not establish a clear tolerance or adaptation pattern with chronic chromium picolinate use. Most trial reports focus on endpoint changes and adverse-event reporting rather than on whether effects fade with continued exposure. (Review) (NIH ODS)
Evidence strength snapshot
The overall human evidence is strongest in type 2 diabetes and weaker or more inconsistent in weight-related, liver-metabolic, and broader metabolic-risk settings. Much of the uncertainty comes from heterogeneous populations, variable outcomes, and incomplete long-term safety and PK characterization. (Review) (Review) (Review)
Other Physiological Contexts Studied
- A small pilot study in overweight adults with binge-eating disorder examined 600 mcg/day chromium picolinate and reported improvement in glucose AUC, but this remains a narrow contextual finding rather than a core research domain. (Research)
- A randomized clinical trial in type 2 diabetes also evaluated cardiometabolic biomarkers and reported between-group improvements in HOMA-IR and some lipid markers, adding biomarker-level context within the broader glycemic literature. (Research)
- Some cited trials assessed body composition, lipid measures, or inflammatory markers alongside glycemic endpoints, which helps explain why the literature is often discussed as metabolic rather than narrowly glucose-only. These findings, however, have not been consistently replicated across all populations. (Research) (Research)
Safety, Interactions & Regulation
Reported adverse effects in trial literature have generally not shown a clear excess over placebo at usual study doses, but long-term safety remains incompletely characterized. Some systematic review sources note limited adverse-event reporting overall, while another review of overweight and obesity trials described events such as watery stools, vertigo, headaches, and urticaria in included studies. (Review) (Review)
Case-based safety context is more cautionary than the trial literature. One cited case report described acute tubular necrosis associated with a chromium picolinate-containing product, which supports signal recognition but does not establish incidence or typical risk. (Research)
The cited NIH ODS source summarizes interaction considerations and notes that chromium may interact with insulin, metformin, levothyroxine, and some other medications or absorption-sensitive contexts. These statements are framework-level safety information rather than proof of frequent clinical interaction events in every setting. (NIH ODS)
In the U.S., the cited FDA source provides food-use GRAS context and does not constitute drug approval or efficacy evaluation. (FDA)
Also in the U.S., the cited NIH ODS document provides dietary-reference, use, and safety-summary context for chromium, but it is not an ingredient-specific FDA approval source. (NIH ODS)
In the EU, the cited EFSA source provides food-use safety and bioavailability context for chromium picolinate as a chromium source within a nutritional-use framework rather than a medicinal approval framework. (EFSA)
Evidence Overview
Human evidence for chromium picolinate is strongest in Diabetes and Glycemic Control, more mixed in Obesity and Weight Regulation and broader endocrine-risk populations, and still limited in Liver Health and other secondary contexts. The dominant human evidence types are randomized oral intervention trials and meta-analyses, supported by a smaller amount of PK, pilot, and case-based safety literature. Confidence is not higher because trial results vary by population, dose, comparator context, and selected outcomes, while long-term safety and pharmacokinetic characterization remain incomplete. (Review) (Review) (Review)
Randomized human trial evidence is most developed in type 2 diabetes. Several trials reported improvement in HbA1c, fasting glucose, postprandial glucose, insulin sensitivity, or related markers, particularly in populations with established diabetes or poorer baseline glycemic control. At the same time, not all intervention studies were favorable, and broader reviews conclude that the overall effectiveness signal is limited by heterogeneity and by the fact that only some studies reached clearly meaningful endpoints. (Research) (Research) (Research) (Review)
Outside established diabetes, the evidence becomes less consistent. Trials in metabolic syndrome, impaired glucose regulation, healthy older adults, and normoglycemic adults reported neutral or mixed findings, which argues against treating chromium picolinate as a uniformly effective metabolic intervention across all populations. This contrast suggests that baseline insulin resistance or dysglycemia may shape the observed response, but the cited literature does not establish a precise responder profile. (Research) (Research) (Research) (Research)
Evidence in PCOS is narrower but reasonably coherent relative to its size. A trial and meta-analysis reported improvement in some insulin-related, BMI, and hormonal outcomes, but this domain remains secondary because it is built on a smaller study base than the diabetes literature. (Research) (Review)
Weight-related evidence is weaker than glycemic evidence. Meta-analyses report only small average body-weight effects with heterogeneity, and individual controlled trials at 200 mcg/day and 400 mcg/day were neutral for meaningful weight or body-composition change. (Research) (Research) (Review) (Review)
Liver-metabolic evidence is currently preliminary. The cited MASLD pilot study reported favorable changes in some biomarkers but not in steatosis intensity or several glycemic endpoints, so this area is not yet mature enough to function as a top-tier evidence domain. (Research)
What would strengthen confidence in future research is not simply more studies, but more comparable studies: clearer population selection, more consistent formulations and outcome measures, better pharmacokinetic characterization, and longer-duration safety reporting. The cited source base supports cautious interpretation rather than broad efficacy framing. (Review) (NIH ODS) (Review)
Evidence Confidence Classification
The overall human evidence for chromium picolinate is Limited / Mixed, based on recurring human trials in diabetes-related settings but important inconsistency across populations, outcomes, and metabolic contexts. (Review) (Review)
Interventional human evidence is substantial enough to show a real research signal, especially in type 2 diabetes and more narrowly in PCOS, but observational and mechanistic context is not matched by uniformly consistent clinical outcomes across all groups. Pharmacokinetic evidence is modest, and regulatory context in the cited sources is framework-level food-use and safety context rather than efficacy approval. (Research) (Review) (FDA) (EFSA)
Similar Ingredients & Comparators
- Chromium chloride
- Chromium nicotinate
- Brewer’s yeast chromium
- Trivalent chromium
- Vanadium compounds
- Alpha-lipoic acid
- Berberine
- Myo-inositol
- Magnesium
- Zinc
- Nicotinamide riboside
- Oral antihyperglycemic agents
- Insulin-sensitizing agents
- Weight-management pharmacotherapies
- Ovulation-related endocrine therapies
Combination Context
Chromium Picolinate + Sulfonylurea therapy:
This combination was studied in adults with type 2 diabetes to assess whether chromium picolinate added to background medication changed glycemic outcomes. The cited trial reported improved insulin sensitivity and glycemic measures with reduced weight gain relative to sulfonylurea plus placebo, but the finding is specific to a medication-background setting rather than chromium picolinate alone in untreated diabetes. (Research)
Chromium Picolinate + Nutritionally balanced diet:
This context was studied in a controlled feeding trial in women to test whether chromium picolinate altered body weight or body composition when diet was tightly managed. The study did not support meaningful weight-loss or body-composition claims in that setting, which makes this a useful interpretation context rather than a supportive efficacy combination. (Research)
Chromium Picolinate + Multi-ingredient product exposure context:
A cited kidney-injury case report involved a chromium picolinate-containing product rather than a clean single-ingredient causality model. This is therefore a safety-attribution context, not a validated beneficial ingredient combination, and it should be interpreted cautiously. (Research)
FAQ
What is this ingredient?
Chromium picolinate is a manufactured complex of trivalent chromium and picolinic acid used as an oral chromium source in human research and commercial products. It is not the naturally occurring food form of chromium, even though chromium itself is a trace mineral found in foods. Human research has focused mainly on glucose and insulin-related outcomes rather than on nutrient-deficiency correction alone. (NIH ODS) (Review)
What does human research study it for?
Human research has studied chromium picolinate mainly for Diabetes and Glycemic Control. Secondary areas include Obesity and Weight Regulation, Women’s Health in PCOS, and a small amount of Liver Health research in MASLD. The strongest and most repeated clinical literature is in type 2 diabetes and insulin-resistance-related outcomes. (Review) (Review) (Research)
What are the best-supported uses?
The best-supported human research area is Diabetes and Glycemic Control, particularly in some adults with type 2 diabetes. Several randomized trials and meta-analyses reported improvements in glycemic markers, although not every study was positive and the overall literature remains mixed. PCOS is a secondary area with narrower but somewhat supportive evidence for insulin-related and reproductive measures. (Research) (Review) (Research)
Where is evidence mixed or limited?
Evidence is mixed or limited in weight management, broader metabolic-risk populations, and liver-metabolic research. Weight-loss effects are small or inconsistent in reviews and were neutral in several controlled trials, while MASLD evidence is currently based on a small pilot study with mixed endpoint results. Trials in healthy or normoglycemic adults have also been neutral, which limits broad generalization. (Review) (Research) (Research) (Research)
How quickly does it act (onset)?
Chromium picolinate does not have a well-defined rapid clinical onset in the cited human literature. Most studies measured outcomes after weeks or months of daily oral use rather than after a single dose or short acute exposure window. A small biomonitoring study shows measurable exposure at 200 mcg/day, but that is not the same as a defined onset of clinical effect. (Research) (Research)
What affects absorption and variability?
Population characteristics appear to affect variability more than any clearly established absorption optimization strategy in the cited library. Positive findings are more common in people with type 2 diabetes or insulin resistance, while normoglycemic adults and some metabolic syndrome cohorts have shown no clear effect. The literature also lacks a fully developed PK framework, which makes variability harder to model precisely. (Research) (Research) (Research) (Review)
Is tolerance reported?
Tolerance in the sense of a diminishing effect over time is not clearly established in the cited sources. Most trials reported endpoint changes and adverse events rather than formal tolerance or tachyphylaxis patterns. Safety reviews indicate that adverse-event rates were not clearly higher than placebo in usual trial settings, but long-term characterization is still incomplete. (Review) (NIH ODS)
Why do studies disagree?
Studies disagree largely because the populations, baseline metabolic status, endpoints, and trial designs differ. Positive findings are more common in established type 2 diabetes, while neutral findings are more common in healthy, normoglycemic, or broader metabolic-risk populations. Differences in dose, background therapy, and study duration also likely contribute to inconsistency. (Research) (Research) (Review)
What ingredients is it commonly combined with and why?
In the cited literature, chromium picolinate is not mainly defined by multi-ingredient combination research. One clear studied context is combination with sulfonylurea therapy in type 2 diabetes, where it was tested as an add-on metabolic intervention rather than as a standalone comparator. Safety literature also includes chromium picolinate-containing products, but those reports are exposure-complexity contexts rather than validated beneficial combinations. (Research) (Research)
What foods naturally contain this ingredient?
Foods naturally contain chromium, but not chromium picolinate as such. Chromium picolinate is a manufactured form used in trials and products, whereas food sources contribute chromium in other forms. That distinction matters because research on chromium picolinate should not automatically be interpreted as research on food chromium intake. (NIH ODS) (Review)
How is it regulated?
In the U.S., the cited FDA source provides food-use GRAS context and does not constitute drug approval or efficacy evaluation. The cited NIH ODS source also provides U.S. dietary-reference and safety-summary context rather than approval status. In the EU, the cited EFSA source provides food-use safety and bioavailability context within a nutritional-use framework rather than medicinal approval. (FDA) (NIH ODS) (EFSA)
Resources
- Chromium – NIH Office of Dietary Supplements – https://ods.od.nih.gov/factsheets/Chromium-HealthProfessional/
- FDA GRAS Notice No. 960 for Chromium Picolinate – U.S. Food and Drug Administration – https://www.fda.gov/media/148805/download
- Safety and bioavailability of chromium picolinate as a source of chromium added for nutritional purposes to food supplements – EFSA – https://www.efsa.europa.eu/en/efsajournal/pub/1883
- Chromium picolinate supplementation in type 2 diabetes – PubMed – https://pubmed.ncbi.nlm.nih.gov/9356027/
- Chromium picolinate in poorly controlled type 2 diabetes – PubMed – https://pubmed.ncbi.nlm.nih.gov/26302914/
- Chromium picolinate added to sulfonylurea therapy – PubMed – https://pubmed.ncbi.nlm.nih.gov/16873787/
- Chromium picolinate in PCOS – PubMed – https://pubmed.ncbi.nlm.nih.gov/26663540/
- Chromium picolinate and MASLD pilot trial – PubMed – https://pubmed.ncbi.nlm.nih.gov/33045675/
- Chromium supplementation for glycemic control review – PubMed – https://pubmed.ncbi.nlm.nih.gov/27261273/
- Chromium evidence scoping review – PMC – https://pmc.ncbi.nlm.nih.gov/articles/PMC10710855/
More from the Supplement Ingredients & Medical Ingredients Encyclopedia
